The gp130-stimulating designer cytokine hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into functional dendritic cells

Exp Hematol. 2000 Apr;28(4):365-72. doi: 10.1016/s0301-472x(00)00126-0.

Abstract

Objective: Hyper-IL-6, a fusion protein of interleukin-6 and its specific receptor, together with stem cell factor leads to the proliferation of primitive hematopoietic progenitor cells. Based on these findings, the current study examined whether hyper-IL-6 promotes the growth of precursor cells that can be further differentiated into dendritic cells in the presence of additional cytokines.

Methods: Dendritic cell cultures were generated from CD34(+) hematopoietic progenitor cells derived either from bone marrow or from peripheral blood. CD34(+) cells were cultured in the presence of cytokines for 2 weeks and then used for phenotyping and T-cell stimulation assays.

Results: Hyper-IL-6 in the presence of stem cell factor induced a 60- to 80-fold expansion of CD34(+) progenitor cells following 2 weeks of culture in serum-free medium. The addition of granulocyte-macrophage colony-stimulating factor to hyper-IL-6 and stem cell factor was essential for the differentiation of expanded progenitor cells into antigen presenting cells capable of inducing a primary T-cell response to soluble protein, which is a typical feature of dendritic cells. Phenotypic analyses confirmed the expansion of immature dendritic cells, which could be further differentiated into mature CD83(+) dendritic cells under the influence of interleukin-4, interleukin-1beta, tumor necrosis factor-alpha, and prostaglandin E(2). The capacity of expanded dendritic cells to stimulate protein-specific CD4(+) T cells was used to stimulate a primary T-helper cell response to the recombinant protein of the hepatitis-B core antigen in healthy donors.

Conclusion: The expansion and differentiation of functional dendritic cells from CD34(+) progenitor cells under serum-free culture conditions allow for the possibility to develop more effective ways to immunize against viral infections and tumor diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigen Presentation / immunology
  • Antigens, CD / biosynthesis
  • Antigens, CD / metabolism*
  • CD4-Positive T-Lymphocytes / cytology
  • CD4-Positive T-Lymphocytes / immunology
  • Cell Differentiation / drug effects
  • Cell Division / drug effects
  • Cells, Cultured
  • Cytokine Receptor gp130
  • Dendritic Cells / cytology*
  • Dendritic Cells / immunology
  • Dinoprostone / pharmacology
  • Flow Cytometry
  • Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology
  • Hematopoietic Stem Cells / cytology*
  • Hematopoietic Stem Cells / drug effects*
  • Hepatitis B Core Antigens / immunology
  • Humans
  • Immunophenotyping
  • Interleukin-1 / pharmacology
  • Interleukin-4 / pharmacology
  • Interleukin-6 / metabolism*
  • Membrane Glycoproteins / metabolism*
  • Oxytocics / pharmacology
  • Receptors, Interleukin / metabolism*
  • Receptors, Interleukin-6
  • Recombinant Fusion Proteins / metabolism
  • Recombinant Proteins
  • Stem Cell Factor / metabolism
  • Stem Cell Factor / pharmacology
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Antigens, CD
  • Hepatitis B Core Antigens
  • IL6ST protein, human
  • Interleukin-1
  • Interleukin-6
  • Membrane Glycoproteins
  • Oxytocics
  • Receptors, Interleukin
  • Receptors, Interleukin-6
  • Recombinant Fusion Proteins
  • Recombinant Proteins
  • Stem Cell Factor
  • Tumor Necrosis Factor-alpha
  • interleukin 6-interleukin 6 receptor fusion protein, recombinant
  • Cytokine Receptor gp130
  • Interleukin-4
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Dinoprostone